Trodusquemine: Availability and Approval Timeline
Trodusquemine (MSI-1436) is a promising compound inhibiting PTP1B, enhancing insulin sensitivity, with potential in treating obesity, diabetes, cancer, and neurodegenerative disorders. Not commercially available, it's in clinical trials, with potential market approval by 2028-2029, pending regulatory challenges.